Skip to main content

Rheumatoid Arthritis

      Further evidence for risk of #MACE with cumulative GC use in RA

      In a national cohort of pts with RA: ⬆️cumulative G
      5 months ago
      Further evidence for risk of #MACE with cumulative GC use in RA In a national cohort of pts with RA: ⬆️cumulative GC exposure associated with ⬆️odds of MACE, regardless of baseline MACE risk Ab1719 #ACR24 @RheumNow https://t.co/RmxokfBXYX
      A#1743
      Are there benefits of getting LDA to remission?
      Remission CDAI <2.8, VLDA 2.8-6, LDA 6-10
      After 1 yr f/u of LD
      5 months ago
      A#1743 Are there benefits of getting LDA to remission? Remission CDAI <2.8, VLDA 2.8-6, LDA 6-10 After 1 yr f/u of LDA, 45% Rem, 40 VLDA, 16 LDA Not in remiss - higher BMI, longer duration, higher resource utilization, worse PRO No clear diff bw remission & VLDA #ACR24 @RheumNow https://t.co/ut7c52JVDr
      Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0
      Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT
      A#1694
      To get one or two lungs for lung transplant? 🫁

      Autoimmune related ILD transplant outcomes?
      145 single (SLT),
      5 months ago
      A#1694 To get one or two lungs for lung transplant? 🫁 Autoimmune related ILD transplant outcomes? 145 single (SLT), 461 double (DLT) Similar 1 yr mortality - HR SLT 1.19 unadjusted, 1.49 adj - not statistically significance @RheumNow #ACR24 https://t.co/uo8WbrNFAm
      A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop
      5 months ago
      A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop HZ vs. unvaxxed grp Incidence of PHN was also lower in the vaccinated group (0.2py vs.1.9py) RZV is effective in preventing HZ & PhN @Rheumnow #ACR25 abs0977 https://t.co/JhYBYnLmhl
      2023 @ACRheum guidance recommends #MediterraneanDiet in RA

      What are barriers/facilitators to following the diet?

      Many
      5 months ago
      2023 @ACRheum guidance recommends #MediterraneanDiet in RA What are barriers/facilitators to following the diet? Many pts are willing to try but don't follow it Barriers➡️ food insecurity & aversions Many are unaware Do you talk to your pts about diet? Ab1673 #ACR24 @RheumNow
      RA-ILD:
      💡Lifetime prevalence seems low but ~40% can have subclincal.
      💡Screen early in symptomatic pts.
      💡RA dise
      RA-ILD: 💡Lifetime prevalence seems low but ~40% can have subclincal. 💡Screen early in symptomatic pts. 💡RA disease control decreases ILD progression and mortality. 💡RA-ILD UIP pattern seems to respond to immunosuppression. #ACR24 @RheumNow https://t.co/q3iACMeYVU
      Subgroup data from SELECT GCA, overall reinforces overall message

      I was curious to see pts previously treated with TCZ;
      5 months ago
      Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3
      ×